STOCK TITAN

HOOKIPA Pharma Inc. - $HOOK STOCK NEWS

Welcome to our dedicated page for HOOKIPA Pharma news (Ticker: $HOOK), a resource for investors and traders seeking the latest updates and insights on HOOKIPA Pharma stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HOOKIPA Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HOOKIPA Pharma's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.32%
Tags
conferences earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
conferences
HOOKIPA Pharma Inc.

Nasdaq:HOOK

HOOK Rankings

HOOK Stock Data

92.04M
58.31M
19.59%
39.38%
0.32%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
NEW YORK

About HOOK

hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a